What do systematic reviews say?

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.56 [0.5, 0.63]
  3 studies · 1564 participants
  Moderate

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 55 participants
  Low

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 76 participants
  Low

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 258 participants
  Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.79, 1.09]
  1 study · 1015 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1108 participants
  High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 204 participants
  Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 634 participants
  Moderate

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor/deutivacaftor vs control

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 603 participants
  High

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor probably leads to lower overall survival compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.71 [0.56, 0.9]
  5 studies · 1263 participants
  Moderate

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  HR 1.19 [0.78, 1.82]
  1 study · 129 participants
  Very low

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival: overall population compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.39 [0.32, 0.46]
  5 studies · 1263 participants
  High

Carboplatin vs cisplatin chemotherapy

Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  RR 0.98 [0.89, 1.08]
  11 studies · 4004 participants
  High

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.25 [0.19, 0.34]
  5 studies · 406 participants
  High

Carboplatin vs cisplatin chemotherapy

Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).

• Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer 2020 · Cochrane Headline outcomes only
  HR 0.99 [0.82, 1.2]
  10 studies · 2515 participants
  High

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

The review found no eligible studies for this question.

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes overall survival Censored compared with hydroxycamptothecin (very low certainty).

• Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
  RR 3.06 [0.16, 60.47]
  1 study · 48 participants
  Very low